[go: up one dir, main page]

PE20090054A1 - Derivados de purina - Google Patents

Derivados de purina

Info

Publication number
PE20090054A1
PE20090054A1 PE2008000169A PE2008000169A PE20090054A1 PE 20090054 A1 PE20090054 A1 PE 20090054A1 PE 2008000169 A PE2008000169 A PE 2008000169A PE 2008000169 A PE2008000169 A PE 2008000169A PE 20090054 A1 PE20090054 A1 PE 20090054A1
Authority
PE
Peru
Prior art keywords
phenyl
purine
piperidin
amino
members
Prior art date
Application number
PE2008000169A
Other languages
English (en)
Inventor
Solana Jorge Salas
Rosales Carmen Almansa
Soliva Robert Soliva
Ustrell Montserrat Fontes
Bernado Marina Virgili
Espuga Josep Comelles
Porras Jose Javier Pastor
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38042749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090054(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of PE20090054A1 publication Critical patent/PE20090054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE PURINA DE FORMULA (I), EN DONDE R1 ES FENILO O HETEROCICLO AROMATICO DE 5 O 6 MIEMBROS DE 1 A 4 HETEROATOMOS DE N, O Y S, OPCIONALMENTE SUSTITUIDOS POR 1 O MAS R3; R2 ES FENILO O HETEROCICLO AROMATICO DE 5 O 6 MIEMBROS, OPCIONALMENTE SUSTITUIDOS POR 1 O MAS R4; R3 Y R4 SON INDEPENDIENTEMENTE ALQUILO(C1-C4), HALOGENO, -CN, -OR6, -SO2R5, -SO2NR6R6, Cy1, ENTRE OTROS. SON SELECCIONADOS: 2-(4-AMINOSULFONILFENIL)AMINO-6-[6-(PIPERIDIN-4-IL)AMINOPIRIDIN-3-IL]-9H-PURINA, 2-[4-(4-MORFOLINO)FENIL]AMINO-6-[6-(PIPERIDIN-3-ILAMINO)PIRIDIN-3-IL]-9H-PURINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS INHIBEN LA VIA DE SENALIZACION JAK/STAT, EN ESPECIAL DE LA CINASA JAK3, POR LO QUE SON UTILES EN EL TRATAMIENTO DE EFERMEDADES INMUNES, AUTOINMUNES O INFLAMATORIAS, RECHAZO DE TRANSPLANTES, ENFERMEDADES NEURODEGENERATIVAS Y PROLIFERATIVAS
PE2008000169A 2007-01-23 2008-01-23 Derivados de purina PE20090054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07381005 2007-01-23

Publications (1)

Publication Number Publication Date
PE20090054A1 true PE20090054A1 (es) 2009-01-26

Family

ID=38042749

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000169A PE20090054A1 (es) 2007-01-23 2008-01-23 Derivados de purina

Country Status (15)

Country Link
US (1) US20100204187A1 (es)
EP (1) EP2118105A1 (es)
JP (1) JP2010526027A (es)
KR (1) KR20090101281A (es)
CN (1) CN101589043A (es)
AR (1) AR064996A1 (es)
AU (1) AU2008208801A1 (es)
BR (1) BRPI0806811A2 (es)
CA (1) CA2674875A1 (es)
CL (1) CL2008000192A1 (es)
MX (1) MX2009007302A (es)
PE (1) PE20090054A1 (es)
RU (1) RU2009131738A (es)
TW (1) TW200902017A (es)
WO (1) WO2008090181A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404674B2 (en) * 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
EP2181110A2 (en) * 2007-07-13 2010-05-05 ADDEX Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
EP2923734B1 (en) 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
ES2500643T3 (es) 2009-04-03 2014-09-30 Verastem, Inc. Compuestos de purina sustituidos con pirimidina como inhibidores de las cinasas
KR20120114224A (ko) * 2009-10-12 2012-10-16 마이렉시스 인코포레이티드 Ｉｋｋ 엡실론 및/또는 ｔｂｋ１의 억제제로서의 아미노-피리미딘 화합물
EP2513114B1 (en) * 2009-12-18 2014-04-02 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
CN103124496B (zh) 2010-10-06 2016-03-30 葛兰素史密丝克莱恩有限责任公司 作为pi3激酶抑制剂的苯并咪唑衍生物
WO2012135801A1 (en) * 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
BR112015002152B1 (pt) * 2012-08-02 2021-04-27 Nerviano Medical Sciences S.R.L. Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos
JP5746777B2 (ja) * 2014-01-21 2015-07-08 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． キナーゼ阻害剤としてのピリミジン置換プリン化合物
TW201613916A (en) * 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
MX2017003930A (es) 2014-09-26 2017-06-30 Gilead Sciences Inc Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
EP3053920B1 (en) * 2015-02-05 2020-04-08 AB Science Compounds with anti-tumoral activity
EA201891024A1 (ru) 2015-12-17 2018-12-28 Джилид Сайэнс, Инк. Соединения-ингибиторы tank-связывающей киназы
CN109790160B (zh) 2016-09-07 2022-11-15 上海海和药物研究开发股份有限公司 吡啶并五元芳香环类化合物、其制备方法及用途
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3947382B1 (en) * 2019-03-26 2025-09-24 Academia Sinica Compounds for uses in pharmacological induction of hbf for treatment of sickle cell disease and beta-thalassemia
CN114685507B (zh) * 2022-04-06 2024-01-12 山东大学 嘌呤胺衍生物类cdk2抑制剂及其制备方法和应用
CN117247387A (zh) * 2022-06-16 2023-12-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US7476670B2 (en) * 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
JP2006522125A (ja) * 2003-03-25 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
EP1610793A2 (en) * 2003-03-25 2006-01-04 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
BRPI0806811A2 (pt) 2011-09-13
KR20090101281A (ko) 2009-09-24
AU2008208801A1 (en) 2008-07-31
MX2009007302A (es) 2009-07-15
RU2009131738A (ru) 2011-02-27
WO2008090181A1 (en) 2008-07-31
JP2010526027A (ja) 2010-07-29
CL2008000192A1 (es) 2008-07-25
US20100204187A1 (en) 2010-08-12
EP2118105A1 (en) 2009-11-18
CN101589043A (zh) 2009-11-25
AR064996A1 (es) 2009-05-06
CA2674875A1 (en) 2008-07-31
TW200902017A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
PE20090054A1 (es) Derivados de purina
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20190475A1 (es) Inhibidores de cdk2/4/6
PE20110991A1 (es) Compuestos de fenil-piridazinona-pirazol-fenilo como inhibidores de pde
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20232038A1 (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
CA2628131A1 (en) Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20050521A1 (es) Derivados de pirazolopiridina
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
PE20141010A1 (es) Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
UY28578A1 (es) Derivados de amida
PE20141557A1 (es) Derivado de pirazoloquinolina
PE20100239A1 (es) Derivados de benzoquinazolina como promotores de la liberacion de hormona paratiroides
PE20191528A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
ES2564010T3 (es) Composición farmacéutica para tratar o prevenir el glaucoma

Legal Events

Date Code Title Description
FD Application declared void or lapsed